|
|
Vaccine Detail
|
irradiated autologous cells |
| Vaccine Information |
- Vaccine Name: irradiated autologous cells
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007628
- Type: DC cells
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: All patients had undergone therapeutic lymphadenectomy prior to the study. The vaccined with BSG awerer usrd one week apart. Those without BSg werer utilized in 2, 4, 8 week periods. The patients were observed with no additional theapy at sites of reoccurence were cut out and revaccinated. . Cyclophosphamide was administered intravenously as 300 mgm/m2 3 days prior to vaccines 1, 4, and 5 to reduce the population of T-suppressor cells. Adjuvant immunotherapy with irradiated autologous melanoma cells and low dose cyclophosphamide seemed to yield better relapse-free survival than the historically reported 10-25% (Elias et al., 1997).
|
| Host Response |
|
|
| References |
Elias et al., 1997: Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Journal of surgical oncology. 1997; 64(1); 17-22. [PubMed: 9040795].
|
|
